Advancing Psychedelic-Assisted Therapies for Mental Health in the U.S.
America is in the midst of a mental health crisis. Tragically, over 130 Americans die by suicide daily, with veterans accounting for more than 20 of these deaths. Emerging psychedelic-assisted therapies offer hope for individuals dealing with treatment-resistant depression, post-traumatic stress disorder, substance use disorders, and generalized anxiety disorder.
Despite their potential, many Americans, including veterans, seek these therapies abroad due to limited availability in the U.S. While the Trump administration accelerated research efforts and the FDA granted Breakthrough Therapy designation to several psychedelic-based treatments, including psilocybin and MDMA, additional federal action is necessary. Improved access and safety measures are crucial for ensuring these therapies reach those in need.
Two years ago, the bipartisan Congressional Psychedelics Advancing Therapies (PATH) Caucus formally requested information to explore safe integration of psychedelic medicine into the U.S. health care system. Feedback from respondents highlighted the non-magical nature of psychedelics, yet emphasized their transformative potential when administered safely and structured.
The need for federal policies establishing nationwide standards is evident. Implementing a national framework will guarantee safe and equitable access. Stakeholders advocate for guidance and verification systems ahead of imminent FDA approvals of psychedelic treatments. Requirements for labeling, crisis response, and integration support must be codified alongside best practices for ‘set and setting.’
Addressing these concerns is essential for realizing the full public health benefits of psychedelic medicine. Congress and federal agencies must confront these challenges to safely incorporate psychedelic-assisted therapies into the American health care system.
The focus must shift to ‘how’ these treatments can be integrated into health care for patients in need. Establishing coherent standards will protect patients, ensure equitable access, and provide life-enhancing benefits to Americans battling severe mental and physical health issues.
Jack Bergman, a retired Marine Corps lieutenant general, represents Michigan’s 1st Congressional District. Lou Correa represents California’s 46th Congressional District. Both are co-chairs of the Congressional PATH Caucus.